安罗替尼联合长春瑞滨+顺铂方案在非小细胞肺癌患者中的应用评价  

Evaluation of application of anrotinib combined with vinorelbine and cisplatin in patients with non-small cell lung cancer

作　　者：杨小芳 李华武 刘苗苗 YANG Xiao-fang;LI Hua-wu;LIU Miao-miao(Department of Clinical Pharmacy,General Hospital of Pingdingshan Shenma medical Group,Pingdingshan,Henan 467000,China;Department of Medical Oncology,General Hospital of Pingdingshan Shenma medical Group,Pingdingshan,Henan 467000,China)

机构地区：[1]平煤神马医疗集团总医院临床药学科,河南平顶山467000 [2]平煤神马医疗集团总医院肿瘤内科,河南平顶山467000

出　　处：《医药论坛杂志》2023年第9期93-96,共4页Journal of Medical Forum

摘　　要：目的 探讨安罗替尼联合长春瑞滨+顺铂方案(NP方案)在非小细胞肺癌(NSCLC)患者中的应用效果。方法 本研究采用前瞻性随机对照分析,研究对象纳入2020年3月—2022年4月平煤神马医疗集团总医院收治的96例晚期NSCLC患者,按照随机号码表法分为对照组和观察组,各48例。对照组患者给予NP方案治疗,观察组患者在此基础上加用安罗替尼治疗,3周为1个周期,两组患者均治疗3个周期,并随访6个月。观察两组治疗3个周期后的临床疗效,比较治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)]水平、血管内皮生长因子(VEGF)水平,无进展生存期(PFS)情况及治疗期间毒副反应发生情况。结果 两组患者均完成3个周期化疗,未出现因严重的毒副反应而停药病例。观察组的疾病控制率(DCR)占比明显高于对照组(P<0.05);两组客观缓解率(ORR)占比比较,差异无统计学意义(P>0.05);治疗3个疗程后,两组血清VEGF及CEA、CA125、CA199水平均明显降低,且观察组低于对照组(P<0.05);随访6个月,观察组4例未发生进展,对照组中有1例未发生进展;观察组PFS时间明显长于对照组(P<0.05);两组毒副反应比较,差异无统计学意义(P>0.05)。结论 安罗替尼联合NP方案可提高晚期NSCLC患者疾病控制率,降低血清VEGF水平,延长无进展生存时间,且未明显增加毒副作用。Objective To investigate the effect of the application of the regimen of anrotinib combined with vinorelbine and cisplatin(NP regimen)in patients with non-small cell lung cancer(NSCLC).Methods A prospective random⁃ized controlled analysis was used in this study.Totally 96 patients with advanced NSCLC admitted to the hospital from March 2020 to April 2022 were included in the study.They were divided into control group and observation group ac⁃cording to the method of random number table,with 48 patients in each group.The patients in the control group were treated with NP regimen,and the patients in the observation group were treated with anrotinib on the basis of this regi⁃men,with 3 weeks as a cycle.The patients in both groups were treated for 3 cycles and followed up for 6 months.The clinical efficacy of the two groups after 3 cycles of treatment was observed.The levels of serum tumor markers[carcino⁃embryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)],vascular endo⁃thelial growth factor(VEGF),progression-free survival(PFS)and adverse reactions during treatment were compared before and after treatment.Results Both groups of patients completed 3 cycles of chemotherapy,and there were no ca⁃ses of drug withdrawal due to serious side effects.The proportion of disease control rate(DCR)in the observation group was higher than that of the control group(P<0.05).There was no statistical significant difference in the proportion of objective response rate(ORR)between the two groups(P>0.05).After 3 courses of treatment,the levels of serum VEGF and CEA,CA125,CA199 in the two groups were significantly decreased,and those in the observation group were lower than the control group(P<0.05).Following up for 6 months,4 cases in the observation group did not progress,and 1 case in the control group did not progress.The PFS time of the observation group was significantly longer than that of the control group(P<0.05).There was no statistical significant difference in side effects between

关 键 词：非小细胞肺癌 安罗替尼 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]